[HTML][HTML] Liposome-based diagnostic and therapeutic applications for pancreatic cancer

F Raza, L Evans, M Motallebi, H Zafar, M Pereira-Silva… - Acta Biomaterialia, 2023 - Elsevier
Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled
as incurable. Chemotherapy continues to be the most popular treatment yet yields a very …

Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications

L Cao, J Wu, X Qu, J Sheng, M Cui, S Liu… - Journal of Experimental …, 2020 - Springer
Pancreatic cancer is one of the most malignant tumors worldwide, and pancreatic ductal
adenocarcinoma is the most common type. In pancreatic cancer, glycolysis is the primary …

[HTML][HTML] Vive la radiorésistance!: converging research in radiobiology and biogerontology to enhance human radioresistance for deep space exploration and …

F Cortese, D Klokov, A Osipov, J Stefaniak… - Oncotarget, 2018 - ncbi.nlm.nih.gov
While many efforts have been made to pave the way toward human space colonization, little
consideration has been given to the methods of protecting spacefarers against harsh cosmic …

Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer

EK Silli, M Li, Y Shao, Y Zhang, G Hou, J Du… - European Journal of …, 2023 - Elsevier
Pancreatic cancer (PC) is an incurable disease with a high death rate in the world
nowadays. Gemcitabine (GEM) and Paclitaxel (PTX) are considered as references of …

[HTML][HTML] Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway

C Yu, S Chen, Y Guo, C Sun - Theranostics, 2018 - ncbi.nlm.nih.gov
Background: Drug resistance is well known as a major obstacle for cancer recurrence and
treatment failure, leading to poor survival in pancreatic cancer, which is a highly aggressive …

Combined exosomal GPC1, CD82, and serum CA19-9 as multiplex targets: a specific, sensitive, and reproducible detection panel for the diagnosis of pancreatic …

D Xiao, Z Dong, L Zhen, G Xia, X Huang, T Wang… - Molecular cancer …, 2020 - AACR
Pancreatic cancer is a highly lethal malignancy with poor prognosis due to the lack of early
symptoms and resultant late diagnosis. Thus, it is extremely urgent to establish a simple and …

Pancreatic cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management

V Jentzsch, J Davis, MBA Djamgoz - Cancers, 2020 - mdpi.com
Simple Summary Pancreatic ductal adenocarcinoma is a devastating disease that is very
hard to treat. Here, we advance and evaluate the notion that the best possible management …

[HTML][HTML] Metabolomic biomarkers of pancreatic cancer: a meta-analysis study

KY Mehta, HJ Wu, SS Menon, Y Fallah, X Zhong… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …

Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal …

T Igarashi, M Fukasawa, T Watanabe… - Annals of …, 2024 - Wiley Online Library
Introduction The prognosis of pancreatic ductal adenocarcinoma (PDAC) in patients with
positive peritoneal washing cytology (CY1) is poor. We aimed to evaluate the results of …

Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives

L Pekarek, O Fraile-Martinez… - Oncology …, 2021 - spandidos-publications.com
Pancreatic cancer has a dire prognosis and will represent the second leading cause of
cancer death in the next 10 years. The multifactorial approach represents one of the main …